1. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. (December 2019) Authors: Qin, Shukui; Chan, Stephen Lam; Sukeepaisarnjaroen, Wattana; Han, Guohong; Choo, Su Pin; Sriuranpong, Virote; Pan, Hongming; Yau, Thomas; Guo, Yabing; Chen, Minshan; Ren, Zhenggang; Xu, Jianming; Yen, Chia-Jui; Lin, Zhong-Zhe; Manenti, Luigi; Gu, Yi; Sun, Yongjian; Tiedt, Ralph; Hao, Lu; Song, We... Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. (August 2020) Authors: Lu, Shun; Chen, Gongyan; Sun, Yuping; Sun, Sanyuan; Chang, Jianhua; Yao, Yu; Chen, Zhendong; Ye, Feng; Lu, Junguo; Shi, Jianhua; He, Jianxing; Liu, Xiaoqing; Zhang, Yiping; Liu, Zhihua; Fang, Jian; Cheng, Ying; Hu, Chunhong; Mao, Weidong; Hu, Yanping; Gong, Youling Journal: Lung cancer Issue: Volume 146(2020) Page Start: 252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. (17th August 2018) Authors: Li, Jin; Xu, Ruihua; Qin, Shukui; Liu, Tianshu; Pan, Hongming; Xu, Jianming; Bi, Feng; Lim, Robert; Zhang, Suzhan; Ba, Yi; Bai, Yuxian; Fan, Nanfeng; Tsuji, Akihito; Yeh, Kun-Huei; Ma, Brigette; Wei, Vivian; Shi, Dongmei; Magherini, Emmanuelle; Shen, Lin Journal: Future oncology Issue: Volume 14:Number 20(2018) Page Start: 2031 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. (September 2021) Authors: Vogel, Arndt; Merle, Philippe; Verslype, Chris; Finn, Richard S.; Zhu, Andrew X.; Cheng, Ann-Lii; Chan, Stephen Lam; Yau, Thomas; Ryoo, Baek-Yeol; Knox, Jennifer; Daniele, Bruno; Qin, Shukui; Wei, Ziwen; Miteva, Yanna; Malhotra, Usha; Siegel, Abby B.; Kudo, Masatoshi Journal: Therapeutic advances in medical oncology Issue: Volume 13(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. (22nd March 2019) Authors: Zhou, Ai‐Ping; Bai, Yuxian; Song, Yan; Luo, Hong; Ren, Xiu‐Bao; Wang, Xiuwen; Shi, Benkang; Fu, Cheng; Cheng, Ying; Liu, Jiyan; Qin, Shukui; Li, Jun; Li, Hanzhong; Bai, Xianzhong; Ye, Dingwei; Wang, Jinwan; Ma, Jianhui Journal: Oncologist Issue: Volume 24:Number 8(2019) Page Start: e702 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (July 2021) Authors: Qin, Shukui; Li, Qiu; Gu, Shanzhi; Chen, Xiaoming; Lin, Lizhu; Wang, Zishu; Xu, Aibing; Chen, Xi; Zhou, Cuncai; Ren, Zhenggang; Yang, Lin; Xu, Li; Bai, Yuxian; Chen, Lei; Li, Jun; Pan, Hongming; Cao, Bangwei; Fang, Weijia; Wu, Wei; Wang, Ge Journal: Lancet gastroenterology and hepatology Issue: Volume 6:Number 7(2021) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. (14th August 2018) Authors: Yang, Chaoxu; Qin, Shukui Journal: Cancer medicine Issue: Volume 7:Number 9(2018:Sep.) Page Start: 4570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study. Issue 24 (20th August 2021) Authors: Harding, James J.; Yang, Tsai‐Sheng; Chen, Yen‐Yang; Feng, Yin‐Hsun; Yen, Chia‐Jui; Ho, Ching‐Liang; Huang, Wen‐Tsung; El Dika, Imane; Akce, Mehmet; Tan, Benjamin; Cohen, Stacey A.; Meyer, Timothy; Sarker, Debashis; Lee, Dae‐Won; Ryoo, Baek‐Yeol; Lim, Ho Yeong; Johnston, Amanda; Bomalaski, John S... Journal: Cancer Issue: Volume 127:Issue 24(2021) Page Start: 4585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Issue 11 (November 2022) Authors: Wainberg, Zev A; Enzinger, Peter C; Kang, Yoon-Koo; Qin, Shukui; Yamaguchi, Kensei; Kim, In-Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, Haci Mehmet; Teixeira, Alexandra; Borg, Christophe; Hitre, Erika; Udrea, Adrian A; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeño; Collins, Helen; ... Journal: Lancet oncology Issue: Volume 23:Issue 11(2022) Page Start: 1430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Issue 8 (August 2022) Authors: Kelley, Robin Kate; Rimassa, Lorenza; Cheng, Ann-Lii; Kaseb, Ahmed; Qin, Shukui; Zhu, Andrew X; Chan, Stephen L; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philipp... Journal: Lancet oncology Issue: Volume 23:Issue 8(2022) Page Start: 995 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗